title: [Osteoporosis].
abstract: The quality of the management of patients with osteoporosis varies by country. The recommendations of the Swiss Association against osteoporosis propose intervention thresholds based on the results of the FRAX tool. Despite increasing number of observational studies with several hundred thousands of patients, it is not possible to conclude to a clear increased risk of cardiovascular disease with calcium intakes. A persistent effect of zoledronic acid is observed even after one single injection. There is no increased fracture risk within 7 months following Denosumab treatment cessation.
authors.affiliation: Service des maladies osseuses, Département des spécialités de médecine, HUG, 1211 Genève. brigitte.uebelhart@hcuge.ch
authors.forename: Brigitte
authors.initials: B
authors.lastname: Uebelhart
authors.affiliation: Service des maladies osseuses, Département des spécialités de médecine, HUG, 1211 Genève.
authors.forename: René
authors.initials: R
authors.lastname: Rizzoli
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology; D000069448:Denosumab; D004164:Diphosphonates / Q000627:therapeutic use; D050723:Fractures, Bone / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D010024:Osteoporosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D012279:Rickets / Q000150:complications / Q000453:epidemiology / Q000628:therapy; D012307:Risk Factors; D000077211:Zoledronic Acid
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000069448:Denosumab; D000077211:Zoledronic Acid; D002118:Calcium
vernacular_title: Ostéoporose.